Alleviant Medical Secures $75M to Advance No-Implant Heart Failure Treatment
• Alleviant Medical closed a $75 million equity financing to fund the ALLAY-HF pivotal trial for its no-implant interatrial shunt system.
• The ALLAY-HF trial is a global, randomized, sham-controlled, double-blinded study evaluating the Alleviant System in heart failure patients.
• The Alleviant System aims to treat heart failure by creating a durable passage between the heart's atria to reduce left atrial pressure.
• Previous studies have demonstrated significant clinical improvements in heart failure patients treated with the Alleviant System.
© Copyright 2025. All Rights Reserved by MedPath